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Protocol
AbstrACt
Introduction Our previous study-level (aggregate data) 
meta-analysis suggested that vitamin D supplements may 
be beneficial for bone density specifically in children with 
vitamin D deficiency. However, the misclassification of 
vitamin D status inherent in study-level data means that the 
results are not definitive and cannot provide an accurate 
assessment of the size of any effect. Therefore, we propose 
to undertake an individual patient data (IPD) meta-analysis to 
determine whether the effect of vitamin D supplementation 
on bone density in children differs according to baseline 
vitamin D status, and to specifically estimate the effect of 
vitamin D in children who are vitamin D deficient.
Methods and analysis This study has been designed to 
adhere to the Preferred Reporting Items for Systematic 
Review and Meta-Analyses of IPD statement. We will 
include randomised placebo-controlled trials of vitamin 
D supplementation reporting bone density outcomes at 
least 6 months after the study commenced in children 
and adolescents (aged <20 years) without coexistent 
medical conditions or treatments causing osteoporosis. 
We will update the search of the original review to cover 
the period 2009–2017, using the same methods as the 
original review. Fully anonymised data on all randomised 
patients will be requested. Outcomes will be femoral neck, 
total hip, lumbar spine and proximal and distal forearm 
bone mineral density, and total body bone mineral content. 
A two-stage IPD meta-analysis will be used to examine the 
effect of baseline serum 25-hydroxyvitamin D (25(OH)D) on 
treatment effect for each bone density outcome. Restricted 
maximum likelihood will be used to estimate the random-
effects meta-analysis models, with 95% CI for summary 
effects. Heterogeneity will be assessed by I2 and potential 
publication bias (small-study effects) and availability bias 
by funnel plots, Egger’s test and Peter’s test.
Ethics and dissemination Ethics approval will not be 
required as the data are to be used for the primary purpose 
for which they were collected and all original individual studies 
had ethics approval. Results of the IPD meta-analysis will be 
submitted for publication in a peer-reviewed journal.
PrOsPErO registration number CRD42017068772.
IntrOduCtIOn 
Optimising bone mass throughout life-
time is critically important for preventing 
fractures at all ages. Of note, fractures occur 
at a similar rate between children and older 
adults.1 Moreover, as in adults,2 low bone 
mineral density (BMD) in children is also 
an important risk factor for childhood frac-
ture.3–6 Therefore, maximising bone mineral 
accretion in childhood has potential bene-
fits in the prevention of childhood fractures, 
though prospective studies are needed to 
further examine this topic.
Improved bone acquisition in childhood is 
also likely to have benefits in the prevention 
of osteoporosis and fracture in later life. This 
strengths and limitations of this study
 ► The major strength of this study is that using 
an individual patient data (IPD) meta-analysis of 
randomised controlled trials (RCTs)  rather than a 
study-level approach allows more accurate risk 
of bias assessments, greater consistency across 
studies in inclusion and exclusion criteria, and—
most crucially for this study—accurate identification 
of subgroups of interest, and examination of effect 
modifiers at the individual  level (rather than the 
study level, which is prone to ecological bias and 
low power).
 ► Pooling across existing studies dramatically 
improves the power to detect genuine subgroup 
effects and treatment effect modifiers, which would 
otherwise require a very large single study.
 ► Importantly, IPD meta-analysis is more feasible and 
less costly than new large-scale RCTs and avoids 
the ethical problem of research waste.
 ► One limitation is the need to address the potential 
influences of variability in vitamin D assays on 
clinical assessment of vitamin D status which will 
be done by a sensitivity analysis.
 ► There is also the potential for bias due to lack of 
availability of IPD, though as we have agreement in 
place to access data in most major trials, this risk is 
minimal, and if necessary this can be managed by 
incorporation of aggregate data into analyses.
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is because low BMD is a major risk factor of fractures in 
older people and BMD in later life is a function of peak 
bone mass (PBM) and the rate of bone loss after PBM is 
achieved.7 8 The detrimental influence of having subop-
timal bone acquisition in childhood seems to be compa-
rably important as age-related bone loss in increasing the 
risk of osteoporosis and related fractures.9 Although the 
specific age at which PBM is achieved is uncertain with 
estimates ranging from late adolescence to the late 30's 
and varying by site measured,10–13 the greatest bone acqui-
sition occurs during puberty14 and up to 90% of PBM is 
achieved in the youth years.15 16 Therefore, it is critically 
important to intervene in childhood and adolescence to 
maximise PBM and so potentially lessen the detrimental 
impact of bone loss later on.
The long-term benefits of improving PBM in childhood 
are likely to be very substantial. Using simulated data, 
Hernandez et al examined the relative importance of 
improving PBM and slowing age-related bone loss in the 
development of osteoporosis.17 It was predicted that the 
onset of osteoporosis would be delayed by 13 years for a 
10% increase in PBM, but only 2 years for a 10% decrease 
in the rate of age-related bone loss before menopause. A 
10% increase in PBM is estimated to be equivalent to 1 SD 
higher BMD at the lumbar spine (LS) from the age of 60. 
As 1 SD decrease in LS, BMD has been associated with a 
60% increase in the risk of hip fracture,18 a 10% increase 
of PBM could translate to approximately a 40% reduction 
in the relative risk of hip fracture.
Vitamin D supplementation of children who are 
vitamin D deficient (serum hydroxyvitamin D (25(OH)
D) <50 nmol/L) appears to be one of the most promising 
options to explore for improving PBM. Childhood vitamin 
D deficiency is considered a significant public health issue 
around the world.19 For example, in a nationally repre-
sentative sample of US children, the prevalence of defi-
ciency was 18% and around 69% children had a level of 
25(OH)D <75 nmol/L.20 Besides rickets, vitamin D defi-
ciency has other potential adverse effects on bone health 
in children by reducing bone mineralisation. Obser-
vational data support the premise that vitamin D defi-
ciency impacts on bone acquisition in older children and 
adolescents.19 21 22 For example, in a cohort of 178 Finnish 
boys and girls aged 14–16 years, serum 25(OH)D levels 
at baseline were significantly correlated with the change 
in LS BMD (r=0.35) and FN BMD (r=0.32) over 3 years. 
In girls who experienced menarche less than 2 years after 
the study began, there was 4% greater accumulation in LS 
BMD in girls who had 25(OH)D ≥37.5 nmol/L than those 
who had 25(OH)D <20 nmol/L (16.7% vs 12.7%).21
Our meta-analysis of six randomised controlled trials 
(RCTs) of vitamin D supplementation in children for 
improving BMD further supports this.23 24 When the base-
line serum 25(OH)D levels from those RCTs were not 
considered in the pooled analysis, the effects of vitamin 
D supplementation on total body (TB) bone mineral 
content (BMC) or hip or forearm BMD were not statisti-
cally significant and effect sizes were small (standardised 
mean difference (SMD) ≤0.10), with a slightly larger, 
but still not statistically significant effect at the LS 
(SMD +0.15, P=0.07). However, when pooled analysis was 
restricted to those studies that had a mean baseline serum 
25(OH)D level of less than 35 nmol/L, we found a larger 
and statistically significant effect of vitamin D supple-
mentation on TB BMC (SMD 0.21, 95% CI 0.01 to 0.41) 
and LS BMD (SMD 0.31, 95% CI 0.00 to 0.61, P=0.05). 
Importantly, the magnitude of the summary effects from 
studies with low mean baseline serum vitamin D levels for 
these bone outcomes were at least 0.2 SMD higher than 
those from studies with higher mean baseline 25(OH)D 
levels (≥35 nmol/L). This analysis is likely to have under-
estimated the effect of vitamin D in deficient children, 
as even the studies in which the study sample’s mean 
baseline 25(OH)D was less than 35 nmol/L, around one 
out of five participants would be expected to have suffi-
cient vitamin D (serum 25(OH)D ≥50 nmol/L), that is, 
there is substantial misclassification of vitamin D status of 
individual study participants. The RCTs published after 
this review found similar results with this meta-analysis, 
supporting the potential for vitamin D supplementation 
to be beneficial in vitamin D deficient but not replete 
children.25–27 However, definitive data are needed to 
underpin health policy and clinical practice for vitamin 
D supplement use in children, and vitamin D testing in 
children and potentially the choice of cut-off for vitamin 
D sufficiency for bone health in children.
Our previous aggregate data meta-analyses are 
potentially subject to ecological bias and study-level 
confounding. We used subgroup analysis to examine the 
difference in meta-analysis results for those studies with 
low (<35 nmol/L) versus high mean baseline vitamin 
D (<35 nmol/L). However, it is well known that differ-
ences at the study level do not necessarily reflect genuine 
differences at the individual level.28 29 For example, the 
different treatment effects in these two subgroups may 
be due to other study-level differences, rather than the 
mean baseline vitamin D level. Further, those studies 
with a mean below 35 nmol/L contain an estimated 20% 
of participants with a baseline value above this value, 
and this misclassification being ignored in the analysis. 
Further research requires the use of individual-level infor-
mation to examine differences in participants’ responses 
to vitamin D supplementation. Therefore, the aims of this 
individual patient data (IPD) meta-analysis are to deter-
mine whether the effect of vitamin D supplementation 
on bone density in children differs according to baseline 
vitamin D status, and specifically estimate the effect of 
vitamin D in children who are vitamin D deficient.
MEthOds And AnAlysIs
This is the protocol for an IPD meta-analysis of RCTs of 
vitamin D supplementation for improving bone density 
outcomes in children to determine whether the effect 
of vitamin D supplementation on bone density in chil-
dren differs according to baseline vitamin D status, 
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and specifically estimate the effect of vitamin D in chil-
dren who are vitamin D deficient. The protocol has 
been designed and written to adhere to the Preferred 
Reporting Items for Systematic Review and Meta-Analyses 
of IPD (PRISMA-IPD) Statement30 and in accordance 
with that we have registered the protocol in the Interna-
tional Prospective Register of Systematic reviews prior to 
commencing the review. Any important protocol amend-
ments will be recorded in PROSPERO and also noted in 
the methods of the final review.
The processes for identification of studies, selection 
of studies for inclusion and extraction of data on study 
characteristics and aggregate study data will be identical 
to that of our published Cochrane review of vitamin D 
supplements for improving BMD in children.23 24 We will 
therefore include all the RCTs included in that review 
(to search date 9 August 2009). We will perform a search 
update for additional potential studies for inclusion, 
using the same search strategies as previously to cover the 
period from 2009 to the current date. The details of these 
methods, together with the additional methods for the 
IPD meta-analysis are presented below.
Inclusion criteria
 ► Types of studies: RCTs of vitamin D supplementation 
compared with placebo, with a treatment period of at 
least 3 months31 will be included.
 ► Types of participants: Trials in children (aged <10 
years) and adolescents (aged 10–19 years) without 
coexistent medical conditions or treatments causing 
osteoporosis will be included.
 ► Types of interventions: Trials of vitamin D supplemen-
tation regardless of type or dose of vitamin D supple-
ment or method of administration, compared with 
placebo will be included.
 ► Types of outcome measures: While fractures in later 
life would be the ideal outcome measure, for inter-
vention studies in children, this would require 
following large numbers of participants for decades. 
Such studies have not been performed to our knowl-
edge, so in this review BMD will be used as a surrogate 
outcome, as is commonly seen in intervention studies 
in children.
Studies reporting areal or volumetric BMD or BMC, 
measured a minimum of 6 months after the study 
commenced, will be included. Measurement sites will 
include femoral neck, total hip, TB, LS and proximal and 
distal forearm. Primary outcome measures will be areal 
or volumetric BMD at the total hip, LS, distal forearm 
and TB BMC, where possible taken as per cent change 
from baseline. Other bone density sites will be considered 
secondary outcomes. Measurement methods can include 
dual X-ray absorptiometry, single-photon or dual-photon 
absorptiometry and peripheral quantitative CT. Studies 
must also have a measure of variance for outcome meas-
ures to be included in the meta-analysis of aggregate data. 
We considered including studies which used quantitative 
ultrasound (QUS) measures but no studies prior to 9 
August 2009 and none that we are aware of subsequent to 
this date have used this outcome. Given that QUS meas-
ures bone characteristics different to actual BMD, and 
the majority of studies report bone density, we have not 
included this outcome in the IPD meta-analysis.
Exclusion criteria
We will exclude non-randomised or uncontrolled trials, 
observational studies, and animal studies and those that 
performed exclusively in neonates (aged <1 month) or 
only reported QUS outcomes.
search methods for identification of studies
To update our search, we will use the same methods in 
an electronic search as the original review, applied from 
2009 to the current date. The search strategies will include 
a search of the Cochrane Central Register of Controlled 
Trials (CENTRAL current issue), MEDLINE (2009 to 
present), EMBASE (2009 to present), CINAHL (2009 to 
present), AMED (2009 to present) and ISI Web of Science 
(2009 to present). There will be no language restric-
tions. The search strategy used for MEDLINE is outlined 
in online supplementary appendix 1 of our published 
review24 with the strategy being adapted as appropriate 
for other databases. We will examine the reference lists 
and ISI citations of all included studies. We will also hand 
search conference abstract issues of key journals (Osteopo-
rosis International, Journal of Bone and Mineral Research, Asia 
Pacific Journal of Clinical Nutrition, Journal of the American 
Dietetic Association, Proceedings of the Nutrition Society, Journal 
of Nutrition) for 2 years prior to the date of the electronic 
search to identify recent trials that are not yet published 
in full, and search trial registries (WHO and US National 
Institutes of Health online registries) for ongoing trials. 
We will also ask all authors of this protocol (who are 
content experts as well as chief investigators on major 
vitamin D RCTS in children) to check the list of included 
studies for omission of potentially relevant studies missed 
by the search.
study selection and data collection for additional studies to 
those in original review
Methods of study selection and data collection for aggre-
gate data (ie, study-level data) are the same as used in the 
original review.23 24 Two researchers will independently 
assess all potentially relevant articles against the inclu-
sion/exclusion criteria. Two researchers will also extract 
aggregate data independently using an existing template. 
We will extract details regarding the study population, 
treatment periods, baseline demographic data, type and 
dose of vitamin D given and bone density outcomes at 
baseline and all other time points measured. We will also, 
where possible, extract data on baseline sex, age, pubertal 
stage, baseline serum vitamin D, method of vitamin D 
assay used and details of laboratory accreditation/quality 
assurance for the assay, physical activity, height, weight, 
body mass index (BMI), dietary calcium intake and 
calcium supplement use, vitamin D intake, levels of sun 
group.bmj.com on February 2, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Winzenberg T, et al. BMJ Open 2018;8:e019584. doi:10.1136/bmjopen-2017-019584
Open Access 
exposure and ethnicity, as well as compliance. We will also 
collect data on adverse effects where available.
Two researchers will assess each trial for risk of bias 
independently, addressing randomisation, allocation 
concealment, blinding of those providing treatment and 
of study participants, completeness of outcome assess-
ment, selective reporting and other potential sources of 
bias as per the Cochrane handbook.32 When necessary, 
we will contact authors of primary studies to obtain addi-
tional information. Differences between reviewers will 
be decided by consensus where possible, with referral 
to a third reviewer if consensus is not possible. If a study 
provides their IPD (see below), we will use it to help 
inform the risk of bias assessment (eg, in relation to base-
line balance, missing data).33
Collection of IPd for all included studies
Key authors of each currently identified major trial (the 
authors of this protocol) have agreed to supply IPD (seven 
studies), and author TW has additional unpublished bone 
density pilot data in 50 deficient children. From means 
and SDs of serum 25(OH)D in these studies, we have esti-
mated the number of individual participants with data for 
each bone density site, by vitamin D status (<50 nmol/L 
being deficient) for both intervention (vitamin D) and 
control groups (table 1). As this shows, the numbers are 
substantial. These are minimum numbers as we anticipate 
additional studies will be identified providing more data. 
We are aware of two such potential studies in 123 children 
with serum 25(OH)D <50 nmol/L (100<35 nmol/L).26 27 
These are substantially higher than in any individual RCT 
(50% more than largest RCT comparison).
Fully anonymised data on all randomised patients will 
be requested. The outcome data requested will be femoral 
neck, total hip, LS and proximal and distal forearm BMD, 
and TB BMC measured at baseline and at any other time 
point during the study (including postsupplementation). 
Participant characteristics requested will be baseline age, 
sex, ethnicity, serum 25(OH)D, dietary calcium intake, 
pubertal stage and physical activity level as well as change 
in 25(OH)D over the trial period and compliance. Data 
will be accepted in any suitable electronic format, but an 
example format detailing the recommended coding will 
be created and offered to all collaborators. Checks on the 
data will be made to ensure data are correctly coded, that 
missing data are correctly identified, that extreme values 
are genuine and to ensure that the data are consistent 
with published results. Data from all trials will be incorpo-
rated into a single database with fields that are consistent 
(as far as possible) across trials.
statistical analyses
We plan to analyse bone density outcomes at 12 months 
as all studies in our systematic review provided bone 
density measures at this time point. Only two studies were 
of longer duration,34 35 namely 2 years, but if sufficient 
studies of this or a longer duration are identified, we will 
consider additional meta-analyses of longer-term data, for 
example, using a multivariate meta-analysis of multiple 
outcomes (multiple time points36).
A two-stage IPD meta-analysis framework will be used to 
examine the effect of baseline serum 25(OH)D on treat-
ment effect for each bone density outcome, that is, hip, 
LS and forearm BMD and TB BMC. In the first stage, each 
trial providing IPD will be analysed separately to provide 
interaction estimates between baseline serum 25(OH)D 
and treatment effect. This will be done using a separate 
linear regression analysis for each bone density outcome, 
where the final (12-month) bone density at a given site 
will be regressed against baseline bone density, baseline 
serum 25(OH)D, the treatment effect and the interaction 
term. For trials that contained multiple centres or for a 
cluster-design, the first stage of the analysis will handle 
the clustering appropriately. The estimates of effect from 
each study’s IPD analysis will be compared with published 
aggregate data for each study.
In the second stage, the interaction estimates will be 
synthesised using a random-effects meta-analysis to 
produce a summary interaction estimate. This two-stage 
approach naturally ensures that clustering of participants 
within trials is accounted for, and that ecological bias 
is avoided in the summary interaction estimate. Where 
some baseline values are missing for some participants in 
a trial, multiple imputation will be applied in each trial 
separately, and the first stage repeated for each imputed 
dataset, with Rubin’s Rules used to combine the results 
to produce final estimates for each trial to take forward 
to stage two.
Restricted maximum likelihood will be used to estimate 
the random-effects meta-analysis models, with 95% CI 
for summary effects derived using the Hartung-Knapp 
approach to appropriately account for uncertainty in 
the estimated variance terms.37 38 Baseline 25(OH)D will 
be primarily analysed as a continuous variable. When 
Table 1 Estimated numbers of individual participants (from studies already agreeing to provide data) with data for each bone 
density outcome, by treatment group and baseline vitamin D status
LS BMD Hip BMD TB BMC Forearm BMD
Baseline 25(OH)D Vitamin D* Control Vitamin D Control Vitamin D Control Vitamin D Control
<50 nmol/L 456 254 318 185 489 323 240 143
≥50 nmol/L 144 73 121 61 85 41 239 143
*Vitamin D=participants receiving active intervention that is, vitamin D supplementation; control=participants receiving placebo.
BMC, bone mineral content; BMD, bone mineral density; LS, lumbar spine; TB, total body.
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analysed as a continuous variable, baseline score will be 
entered as a linear term primarily, but sensitivity anal-
ysis will examine if non-linear trends are more plausible, 
using fractional polynomials. Although power is drasti-
cally reduced when dichotomising, baseline 25(OH)D 
will also be examined as a binary variable in secondary 
analysis (in keeping with published studies), with a cut-off 
of 50 nmol/L used a priori to define low and high levels, 
as this is the most widely accepted definition of vitamin D 
deficiency,39 but we will also undertake a secondary anal-
ysis with a lower cut-off of 35 nmol/L in view of this being 
a potential cut-off identified in the original aggregate 
data meta-analysis. This is feasible as we have estimated 
that the numbers of participants with levels <35 nmol/L 
range from 226 for hip BMD to 480 for TB BMC.
Note that if there are repeated follow-up scores (eg, at 
6 months and 12 months), the first stage will be adapted 
to include a repeated measures model where all follow-up 
times are jointly analysed, and the correlation among 
repeated measures from the same participants accounted 
for.40 This approach can naturally handle missing 
follow-up scores for some participants, under a missing 
at random assumption. A multivariate meta-analysis will 
then be considered in the second stage of our meta-anal-
yses, to jointly synthesis the multiple interaction estimates 
at the time points from each study, accounting for their 
correlation.36 If different studies use different BMD 
measures, that is, volumetric versus areal BMD, then the 
first stage will produce results as SMDs for synthesis in the 
second stage.
Overall treatment effects and treatment effects for 
each vitamin D subgroup will be produced in such a 
two-stage approach. Other possible predictors of treat-
ment response (age (continuous), sex, pubertal status 
(eg, prepubertal vs postpubertal), BMI, body composi-
tion, compliance and method of vitamin D assay) will also 
be investigated in secondary analyses. A sensitivity anal-
ysis will also be performed to determine any difference in 
effects according to whether the vitamin D assay used was 
or was not standardised according to vitamin D standard-
isation program methods. All summary and study-specific 
results will be presented in tables and via forest plots, 
with heterogeneity assessed by I2, estimates of between-
study variance and 95% prediction intervals. The entire 
process will be reported according to the PRISMA-IPD 
guidelines.30
Where possible, to reduce the potential for availability 
bias, aggregate data from studies not providing their IPD 
will be incorporated in the meta-analysis using novel 
methods.41 For example, if interactions can be obtained 
directly from study authors or publications of the non-IPD 
studies, these will be incorporated in the second stage 
of our meta-analyses. The potential for publication bias 
(small-study effects) and availability bias will be examined 
using contour-enhanced funnel plots and suitable tests 
such as Egger’s test and Peter’s test.42 If necessary, sensi-
tivity analysis excluding studies at high risk of bias will be 
undertaken.
The Grading of Recommendations Assessment, Devel-
opment and Evaluation system will be used to rate the 
quality of the body of evidence for each outcome as 
per the Cochrane Handbook for Systematic reviews of 
Interventions.43
rEsults
The entire IPD meta-analysis process, including results will 
be reported according to the PRISMA-IPD guidelines.30
dIsCussIOn
Definitive data on the effectiveness of vitamin D supple-
ments for improving bone density in deficient children 
are needed to inform health policy and clinical practice 
for vitamin D supplement use and vitamin D testing in 
children and to provide better evidence to support the 
minimum threshold for vitamin D sufficiency to optimise 
bone health in children. In the absence of definitive data 
confirming effectiveness and accurately estimating the 
magnitude of any effect, it is not possible to model health 
economic benefits of approaches to assessing and opti-
mising vitamin D status in children. In a highly cost-ef-
fective way, this IPD meta-analysis will provide a definitive 
answer to the question of whether supplementing vitamin 
D-deficient children provides worthwhile benefits for 
bone density.
This is critical information as there is an urgent need to 
develop approaches to improve PBM in childhood. Based 
on current evidence, vitamin D supplementation of chil-
dren who are vitamin D deficient is one of the most prom-
ising options and has potential to have a major impact 
on the risk of fracture in later life. The accumulation of 
even small annual improvements in acquisition of bone 
mass are likely to be important—a 10% increase in PBM 
could in theory result in around a halving of the relative 
risk of hip fracture in older adult life. Given the impacts 
of osteoporotic fracture on the health system, community 
and individuals, and that fractures and their associated 
disease burden are increasing, putting in place effective 
and efficient strategies for long-term prevention is criti-
cally important.
An IPD meta-analysis involves obtaining, cleaning, 
harmonising and then synthesising raw data from existing 
studies.29 33 In contrast to our previous aggregate data 
meta-analyses, using individual-level information allows 
more accurate risk of bias assessments, more consistency 
across studies in inclusion and exclusion criteria, and—
most crucially for this study—accurate identification of 
subgroups of interest, and examination of effect modi-
fiers at the individual level (rather than the study level, 
which is prone to ecological bias and low power28 44). 
Pooling across existing studies, also dramatically improves 
the power to detect genuine subgroup effects and treat-
ment effect modifiers, which would otherwise require a 
very large single study.45
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IPD meta-analysis is more feasible and less costly than 
new large-scale RCTs and avoids the ethical problem of 
research waste.46 It will eliminate the need for further 
costly and complex RCTs in this area. Such RCTs would 
be likely to be challenging from a feasibility perspective. 
Our pilot work identified major feasibility challenges for 
recruitment, namely low response rates and difficulty 
reaching and identifying children who are vitamin D defi-
cient. For example, when recruiting through high schools 
the response rate was only 14.4% from a mail-out to 1070 
parents/children with a prevalence of vitamin D defi-
ciency of only 22%47 possibly due to healthy responder 
bias. Even if feasible, a large-scale RCT of vitamin D 
supplementation with bone density outcomes targeting 
this population would be very expensive. Roughly 440 
children would be required to have power to detect 
potentially clinically important differences of around 
1.5% per annum in LS and femoral neck BMD. We esti-
mate that such a study in Australia would cost a minimum 
of $A750 000 taking into account the unusually high costs 
of staffing needed to overcome recruitment challenges, 
as well as the costs of screening serum 25(OH)D levels 
(estimate five tests to identify one eligible child). By 
comparison, we estimate the cost of implementing this 
IPD meta-analysis will be close to a quarter of this.
In summary, given the impacts of osteoporotic fracture 
on the health system, community and individuals, putting 
in place effective and efficient strategies for long-term 
prevention is critically important. This IPD meta-analysis 
will provide the most robust evidence to date to delineate 
the role of vitamin D in optimising bone development in 
children and underpin appropriate evidence-based clin-
ical and public health actions in this area.
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